{
    "paper_id": "60c988847aab22a9793b64c816f21e105f8074b0",
    "metadata": {
        "title": "Consensus Guidelines for Interventional Cardiology Services Delivery During Interventional cardiology working group POSITION STATEMENT",
        "authors": [
            {
                "first": "St",
                "middle": [],
                "last": "Vincent&apos;s Hospital",
                "suffix": "",
                "affiliation": {
                    "laboratory": "",
                    "institution": "Liverpool Hospital",
                    "location": {
                        "region": "NSW",
                        "country": "Australia"
                    }
                },
                "email": "intervention@csanz.edu.au"
            }
        ]
    },
    "abstract": [
        {
            "text": "Executive Summary",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Abstract"
        },
        {
            "text": "The global COVID-19 pandemic poses an unprecedented 45 stress on healthcare systems internationally. These Health 46 system-wide demands call for efficient utilisation of resour-47 ces at this time in a fair, consistent, ethical and efficient 48 manner would improve our ability to treat patients. Excellent 49 co-operation between hospital units (especially ICU, ED and 50 cardiology) is critical in ensuring optimal patient outcomes.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Abstract"
        },
        {
            "text": "51",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Abstract"
        }
    ],
    "body_text": [
        {
            "text": ". In Australia, our available PPE appears to be in 108 short supply. Therefore, the indication and urgency of inter-109 ventional cardiac procedures needs to be balanced against 110 the risks. The potential need for exposed staff to be ''self-111 quarantined\" or infected staff to be off-duty (or worse admit-112 ted as patients) will hinder service delivery and in some 113 instances rendering it non-viable. ",
            "cite_spans": [],
            "ref_spans": [],
            "section": ""
        }
    ],
    "bib_entries": {
        "BIBREF0": {
            "ref_id": "b0",
            "title": "Critical organizational issues for 901 cardiologists in the COVID-19 outbreak",
            "authors": [
                {
                    "first": "G",
                    "middle": [
                        "G"
                    ],
                    "last": "Stefanini",
                    "suffix": ""
                },
                {
                    "first": "E",
                    "middle": [],
                    "last": "Azzolini",
                    "suffix": ""
                },
                {
                    "first": "G",
                    "middle": [],
                    "last": "Condorelli",
                    "suffix": ""
                }
            ],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF2": {
            "ref_id": "b2",
            "title": "Consensus Guidelines for Interventional Cardiology Services Delivery During COVID-19 Pandemic in Australia and New Zealand",
            "authors": [
                {
                    "first": "Sth",
                    "middle": [],
                    "last": "Lo",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "Heart, Lung and Circulation",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {
                "DOI": [
                    "10.1016/j.hlc.2020.04.002"
                ]
            }
        },
        "BIBREF3": {
            "ref_id": "b3",
            "title": "Clinical characteristics 916 of 138 hospitalized patients with 2019 novel coronavirus-infected pneu-917 monia in Wuhan, China",
            "authors": [
                {
                    "first": "D",
                    "middle": [],
                    "last": "Wang",
                    "suffix": ""
                },
                {
                    "first": "B",
                    "middle": [],
                    "last": "Hu",
                    "suffix": ""
                },
                {
                    "first": "C",
                    "middle": [],
                    "last": "Hu",
                    "suffix": ""
                },
                {
                    "first": "F",
                    "middle": [],
                    "last": "Zhu",
                    "suffix": ""
                },
                {
                    "first": "X",
                    "middle": [],
                    "last": "Liu",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "Zhang",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "JAMA",
            "volume": "323",
            "issn": "",
            "pages": "1061--1070",
            "other_ids": {}
        },
        "BIBREF4": {
            "ref_id": "b4",
            "title": "Catheterization laboratory considerations during the corona-920 virus (COVID-19) Pandemic: from ACC's interventional council and 921 SCAI",
            "authors": [
                {
                    "first": "Fgp",
                    "middle": [],
                    "last": "Welt",
                    "suffix": ""
                },
                {
                    "first": "P",
                    "middle": [
                        "B"
                    ],
                    "last": "Shah",
                    "suffix": ""
                },
                {
                    "first": "H",
                    "middle": [
                        "D"
                    ],
                    "last": "Aronow",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [
                        "E"
                    ],
                    "last": "Bortnick",
                    "suffix": ""
                },
                {
                    "first": "T",
                    "middle": [
                        "D"
                    ],
                    "last": "Henry",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [
                        "W"
                    ],
                    "last": "Sherwood 919",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "J Am Coll Cardiol )",
            "volume": "",
            "issn": "20",
            "pages": "34566--34572",
            "other_ids": {
                "DOI": [
                    "10.1016/j.jacc.2020.03.021"
                ]
            }
        },
        "BIBREF5": {
            "ref_id": "b5",
            "title": "Features, 924 evaluation and treatment coronavirus (COVID-19) StatPearls",
            "authors": [
                {
                    "first": "M",
                    "middle": [],
                    "last": "Cascella",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [],
                    "last": "Rajnik",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [],
                    "last": "Cuomo",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [],
                    "last": "Dulebohn",
                    "suffix": ""
                },
                {
                    "first": "R",
                    "middle": [
                        "D"
                    ],
                    "last": "Napoli",
                    "suffix": ""
                }
            ],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF6": {
            "ref_id": "b6",
            "title": "Treasure Island (FL): StatPearls Publishing",
            "authors": [],
            "year": 2020,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF7": {
            "ref_id": "b7",
            "title": "Routine invasive 927 strategies versus selective invasive strategies for unstable angina and 928 non-ST elevation myocardial infarction in the stent era",
            "authors": [
                {
                    "first": "J",
                    "middle": [
                        "P"
                    ],
                    "last": "Fanning",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "Nyong",
                    "suffix": ""
                },
                {
                    "first": "I",
                    "middle": [
                        "A"
                    ],
                    "last": "Scott",
                    "suffix": ""
                },
                {
                    "first": "C",
                    "middle": [
                        "N"
                    ],
                    "last": "Aroney",
                    "suffix": ""
                },
                {
                    "first": "D",
                    "middle": [
                        "L"
                    ],
                    "last": "Walters",
                    "suffix": ""
                }
            ],
            "year": 2016,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {
                "DOI": [
                    "10.1002/14651858.CD004815.pub4"
                ]
            }
        },
        "BIBREF8": {
            "ref_id": "b8",
            "title": "Fourth 932 universal definition of myocardial infarction",
            "authors": [
                {
                    "first": "K",
                    "middle": [],
                    "last": "Thygesen",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [
                        "S"
                    ],
                    "last": "Alpert",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [
                        "S"
                    ],
                    "last": "Jaffe",
                    "suffix": ""
                },
                {
                    "first": "B",
                    "middle": [
                        "R"
                    ],
                    "last": "Chaitman",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [
                        "J"
                    ],
                    "last": "Bax",
                    "suffix": ""
                },
                {
                    "first": "D",
                    "middle": [
                        "A"
                    ],
                    "last": "Morrow",
                    "suffix": ""
                }
            ],
            "year": 2018,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF10": {
            "ref_id": "b10",
            "title": "How to balance acute myocardial infarction and 935 COVID-19: the protocols from SichuanProvincial People's Hospital",
            "authors": [
                {
                    "first": "J",
                    "middle": [],
                    "last": "Zeng",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "Huang",
                    "suffix": ""
                },
                {
                    "first": "L",
                    "middle": [],
                    "last": "Pan",
                    "suffix": ""
                }
            ],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF13": {
            "ref_id": "b13",
            "title": "National Heart Foundation of Australia & Cardiac Society of Australia 940 and New Zealand: Australian Clinical Guidelines for the Management of",
            "authors": [],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF14": {
            "ref_id": "b14",
            "title": "Acute Coronary Syndromes",
            "authors": [],
            "year": 2016,
            "venue": "Heart Lung Circ",
            "volume": "25",
            "issn": "",
            "pages": "895--951",
            "other_ids": {
                "DOI": [
                    "10.1016/j.hlc.2016.06.789"
                ]
            }
        },
        "BIBREF17": {
            "ref_id": "b17",
            "title": "Consensus document of the Interventional Cardiol-945 ogy and Heart Rhythm Associations of the Spanish Society of Cardiology 946 on the management of invasive cardiac procedure rooms during the 947 COVID-19 coronav Q15 irus outbreak",
            "authors": [
                {
                    "first": "Garc\u00eda",
                    "middle": [],
                    "last": "Seara",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "REC Interv Cardiol",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {
                "DOI": [
                    "10.24875/RECICE.M20000116)"
                ]
            }
        },
        "BIBREF18": {
            "ref_id": "b18",
            "title": "Clinic Q16 with SARS-CoV-2 pneumonia in Wuhan, China: a 954 single-centered, retrospective, observational study",
            "authors": [
                {
                    "first": "X",
                    "middle": [],
                    "last": "Yang",
                    "suffix": ""
                },
                {
                    "first": "Y",
                    "middle": [],
                    "last": "Yu",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "Xu",
                    "suffix": ""
                },
                {
                    "first": "H",
                    "middle": [],
                    "last": "Shu",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "Xia",
                    "suffix": ""
                },
                {
                    "first": "H",
                    "middle": [],
                    "last": "Liu",
                    "suffix": ""
                }
            ],
            "year": null,
            "venue": "Lancet Respir Med",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF20": {
            "ref_id": "b20",
            "title": "COVID-19: fear and anxiety in frontline Clinicians",
            "authors": [
                {
                    "first": "J",
                    "middle": [],
                    "last": "Ting",
                    "suffix": ""
                }
            ],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF23": {
            "ref_id": "b23",
            "title": "in China",
            "authors": [],
            "year": 2020,
            "venue": "Med Sci Monit",
            "volume": "961",
            "issn": "2020",
            "pages": "",
            "other_ids": {
                "DOI": [
                    "10.12659/MSM.923549"
                ]
            }
        }
    },
    "ref_entries": {
        "FIGREF0": {
            "text": "] A.S.[ T D $ F I R S T N A M E . E ] [ T D $ S U R N A M E ] Yong[ T D $ S U R N A M E . E ] b,c , [ T D $ F I R S T N A M E ] A.[ T D $ F I R S T N A M E . E ] [ T D $ S U R N A M E ] Sinhal[ T D $ S U R N A M E . E ] d , [ T D $ F I R S T N A M E ] S.[ T D $ F I R S T N A M E .E ] [ T D $ S U R N A M E ] Shetty[ T D $ S U R N A M E . E ] e , [ T D $ F I R S T N A M E ] A.[ T D $ F I R S T N A M E . E ] [ T D $ S U R N A M E ] McCann[ T D $ S U R N A M E . E ] f,g , [ T D $ F I R S T N A M E ] D.[ T D $ F I R S T N A M E . E ] [ T D $ S U R N A M E ] Clark[ T D $ S U R N A M E . E ] h , 7 [ T D $ F I R S T N A M E ] L.[ T D $ F I R S T N A M E . E ] [ T D $ S U R N A M E ] Galligan[ T D $ S U R N A M E . E ] i , [ T D $ F I R S T N A M E ] S.[ T D $ F I R S T N A M E . E ] [ T D $ S U R N A M E ] El-Jack[ T D $ S U R N A M E . E ] j , [ T D $ F I R S T N A M E ] M.[ T D $ F I R S T N A M E . E ] [ T D $ S U R N A M E ] Sader[ T D $ S U R N A M E . E ] c,k , [ T D $ F I R S T N A M E ] R.[ T D $ F I R S T N A M E . E ] [ T D $ S U R N A M E ] Tan[ T D $ S U R N A M E . E ] l , [ T D $ F I R S T N A M E ] H.[ T D $ F I R S T N A M E . E ] [ T D $ S U R N A M E ] Hallani[ T D $ S U R N A M E . E ] l , [ T D $ F I R S T N A M E ] P.[ T D $ F I R S T N A M E . E ] [ T D $ S U R N A M E ] Barlis[ T D $ S U R N A M E . E ] m,n,o,p , 8 [ T D $ F I R S T N A M E ] R.[ T D $ F I R S T N A M E . E ] [ T D $ S U R N A M E ] Sechi[ T D $ S U R N A M E . E ] q , [ T D $ F I R S T N A M E ] E.[ T D $ F I R S T N A M E . E ] [ T D $ S U R N A M E ] Dictado[ T D $ S U R N A M E . E ] q , [ T D $ F I R S T N A M E ] A.[ T D $ F I R S T N A M E . E ] [ T D $ S U R N A M E ] Walton[ T D $ S U R N A M E . E ] r,s , [ T D $ F I R S T N A M E ] G.[ T D $ F I R S T N A M E . E ] [ T D $ S U R N A M E ] Starmer[ T D $ S U R N A M E . E ] t , [ T D $ F I R S T N A M E ] R.[ T D $ F I R S T N A M E . E ] [ T D $ S U R N A M E ] Bhagwandeen[ T D $ S U R N A M E . E ] u,v ,9 [ T D $ F I R S T N A M E ] D.Y.[ T D $ F I R S T N A M E . E ] [ T D $ S U R N A M E ] Leung[ T D $ S U R N A M E . E ] a,w , [ T D $ F I R S T N A M E ] C.P.[ T D $ F I R S T N A M E . E ] [ T D $ S U R N A M E ] Juergens[ T D $ S U R N A M E . E ] a,w , [ T D $ F I R S T N A M E ] R.[ T D $ F I R S T N A M E . E ] [ T D $ S U R N A M E ] Bhindi[ T D $ S U R NA M E . E ] c,x , [ T D $ F I R S T N A M E ] D.W.M.[ T D $ F I R S T N A M E . E ] [ T D $ S U R N A M E ] Muller[ T D $ S U R N A M E . E ] w,y , 10 [TD$FIRSTNAME]R.[ T D $ F I R S T N A M E . E ] [ T D $ S U R N A M E ] Rajaratnum[ T D $ S U R N A M E . E ] a,w,z , [ T D $ F I R S T N A M E ] J.K.[ T D $ F I R S T N A M E . E ] [ T D $ S U R N A M E ] French[ T D $ S U R N A M E . E ] a,w,z , [ T D $ F I R S T N A M E ] L.[ T D $ F I R S T N A M E . E ] [ T D $ S U R N A M E ] Kritharides[ T D $ S U R N A M E . E ] b,c,A , 11 on behalf of the Interventional council of CSANZ and COVIDimprove our ability to treat patients. Excellent 49 co-operation between hospital units (especially ICU, ED and 50 cardiology) is critical in ensuring optimal patient outcomes. 51 The purpose of this document is to provide practical guide-52 lines for the effective use of interventional cardiology ser-53 vices in Australia and New Zealand. The document will be 54 updated regularly as new evidence and knowledge is gained55 with time.",
            "latex": null,
            "type": "figure"
        },
        "FIGREF1": {
            "text": "283 cases with 1 fatality as of March 29th 2020.",
            "latex": null,
            "type": "figure"
        },
        "FIGREF2": {
            "text": "potentially resulting in many thousands of infec-119 tions within weeks despite ''social distancing\" and ''lock-120 down\" measures which can take 3-6 weeks to show an 121 impact.",
            "latex": null,
            "type": "figure"
        },
        "FIGREF4": {
            "text": "but clinical decision on a case-by-case 282 basis should be made. Echocardiography may be a use-283 ful tool in this context.284 o COVID-19 ''Low exposure risk\" can be brought to the 285 catheter laboratory with staff observing appropriate 286 PPE during procedure performance (may be routine 287 care in this case) and cleaning procedures applied as patients are in the unknown category, for exam-298 ple, non-English speaking patient and there is an urgent 299 clinical need, it is appropriate to treat as ''high exposure 300 risk\" of COVID-19.",
            "latex": null,
            "type": "figure"
        },
        "FIGREF5": {
            "text": "possibility of myocarditis should always be consid-312 ered and possibly excluded using CTCA where possible 313 o Point-of-care COVID-19 testing when available may 314 reduce time required to stratify patient's COVID-19 risk 315 but the accuracy of this has not been demonstrated in 316 practice 317 iii) Acute coronary syndrome (STEMI) 318 o Patients with ''low exposure risk\" of COVID-19 can be 319 brought to the catheter lab with appropriate PPE and 320 cleaning procedures applied as per usual practice 321 o In units where staffing levels are compromised and pri-322 mary PCI cannot be offered (including lack of PPE) then 323 fibrinolysis may be appropriate if patients are lysis-324 eligible 325 o In busy primary PCI units, simultaneous presentations of 326 2 or more STEMI patients is not infrequent. In this situa-327 tion, it is unlikely that more than 1 patient will receive 328 primary PCI (time delay with PPE, terminal cleaning time, 329 avoid contamination of a ''clean Lab\", lowered staffing 330 levels), then fibrinolysis would be an option 331 o Fibrinolytic agents should be made available where 332 patients are likely to be treated (eg Emergency depart-333 ments, coronary care units, catheter laboratories) 334 o Cardiologists should re-familiarise themselves with the 335 indications and contraindications of fibrinolytic agents 336 they are using (commonly TNK-tPA single bolus 337 weight-adjusted dosing) 338 o Fibrinolytic therapy could be considered in lytic-eligible 339 patients with ''High exposure\" risk of COVID-19 as 340 suggested by Sichuan Provincial people's hospital flow 341 chart [10] (see also protocols from Cairns hospital, 342 Nepean Hospital, Eastern Heart Clinic and Zaman 343 et al.).344 o Lengthy treatment delay in delivering cardiac catheter-345 isation is likely to arise due to the need fibrinolysis is used for STEMI, patients aged 75 353 years should receive 1 / 2 weight-adjusted TNK-tPA dose 354 with clopidogrel given (n.b.: omit the loading dose and 355 use 75 mg daily) [11] as Ticagrelor should not be given at 356 the time of fibrinolysis administration. Enoxaparin 357 should be given at a dose of 30 mg IV bolus (<75 years) 358 and then 1 mg/kg SCI BD except for patients 75 years 359 where enoxaparin is given at 0.75 mg/kg SCI BD with no 360 IV bolus [11]361 o ''High exposure risk\" COVID-19 patients should only be 362 brought into the catheter laboratory if there is a strong 363 indication that urgent cardiac catheterisation would 364 alter their short-term prognosis ie clear evidence of 365 ongoing severe ischaemia by the presence of 366 i) Symptoms and ECG changes refractory to medical (or 367 fibrinolytic) therapy, or 368 ii) Haemodynamic instability 369 iii) Large STEMI e.g. left main/anterior territory or infe-370 rior territory with hypotension or ischaemic 371 arrhythmia 372 o Patients with severe pneumonia or ARDS should not be 373 brought to the catheter laboratory and multi-disciplin-374 ary management discussions are likely necessary (eg 375 escalation to intubation or haemodynamic support, 376 risk/benefits of invasive angiography/PCI or decision 377 to palliate) 378 o The possibility of myocarditis should be considered and 379 possibly excluded using CTCA where possible 380 o Echocardiography is also useful and hand-held devices 381 may be advantageous because of their ease-of-use and 382 simpler cleaning (eg GE V-scan TM and Philips 383 Lumify TM ). 384 iv) Structural interventions 385 a) TAVI -the patient group in question can be very elderly 386 and are already vulnerable to death from infections. The 387 overall value and clinical urgency of TAVI would require 388 joint decision making between Heart team/TAVI 389 implanter/referring cardiologist/patient and the host 390 institution. TAVI offers shortened hospital stays and 391 reduced morbidity compared to surgical Aortic valve 392 replacement (SAVR). Compared to SAVR, TAVI may 393 reduce demand for ICU and anaesthetic services during 394 a pandemic. If TAVI is performed, pre-procedural screen-395 ing and COVID-19 PCR may aid in reducing risk to staff. 396 Although a significant proportion of TAVI are done under 397 conscious sedation, GA and intubation is a consideration 398 especially to mitigate viral spread in the event of unfore-399 seen intubation or CPR requirement. 400 b) Mitral Clip -unstable patients could be considered if 401 resources allow, lower risk patients should be this article in press as: Lo STH, et al. Consensus Guidelines for Interventional Cardiology Services Delivery During COVID-19 Pandemic in Australia and New Zealand. Heart, Lung and Circulation (2020), https://doi.org/10.is to reduce infection risk to HCW and minimising 411 virus contamination of laboratories. If there is more than 1 412 laboratory available in a cardiology unit, then one should be 413 made a dedicated COVID-19 laboratory so that the others are 414 ''clean\". This does not guarantee that the ''clean lab\" will not 415 be contaminated at any time but serves to minimise risk and 416 maximise patient flow (especially for ''low exposure risk\" 417 patients) in the catheter laboratory. If time permits, explore 418 with hospital engineering if the laboratories can be made 419 ''negatively pressured\" and understanding of the air condi-420 tioning system is important as this may expose other parts of 421 the hospital with a single procedure. 422 Accessory Catheter Laboratory Equipment 423 It may be pertinent to investigate if accessory catheter labo-424 ratory equipment is easy to clean post-treatment of a ''high 425 exposure risk\" patient. Such equipment should not be left in 426 the catheter laboratory and kept in a ''clean\" area. It is 427 especially important to understand what is being cleaned 428 during a ''terminal cleaning process\" and the time required 429 before the lab can be re-used. All equipment in the lab during 430 a case needs cleaning and covers may be useful. Cath lab 431 possessing already integrated equipment which doesn't need 432 cleaning such some FFR and OCT systems means these are 433 readily available for procedures. However some systems 434 such as IVUS and rotational atherectomy are mobile may 435 not be made available if cleaning is not possible. This may 436 potentially hinder treatment options. Portable iSTAT 437 machines may be placed in the laboratory to be used during 438 an urgent procedure and to be cleaned after. 439 Venue Ambulance transferred patients should be taken to the 440 Emergency department especially if clinically unstable as 441 there are usually limited medical staff supervising wards. 442 This may be the single most controllable entry point to any 443 hospital to minimise staff infection risk and can avoid un-444 screened/non-risk assessed patients directly entering the 445 lab. Pre-catheter lab assessment may be proposed in a ded-446 icated single ''hot\" room in a coronary care unit (when 447 patients numbers demands increase) for transferred 448 patients. Depending on the choice of reperfusion therapy 449 (Lysis or Primary PCI), risk-assessment, imaging (CXR), 450 transthoracic echocardiography, intubation may be done 451 prior to transfer to the catheter laboratory. Such a ''Hot 452 room\" should preferably be negatively pressured but avail-453 ability is extremely limited. They should be terminally 454 cleaned after use. Alternatively, fibrinolytic therapy may 455 be offered. If patient requires airway management, there 456 is a lowered intubation threshold for ''high exposure risk\" are within a State health care network or district 464 should have early discussions regarding service availability 465 across their areas. It may be prudent to limit one centre to be 466 receiving urgent primary PCI for each district/network as in 467 Italy [1]. This may be co-ordinated with conversion of smaller 468 networked centres to fibrinolysis-first strategy despite the 469 presence of a catheter laboratory on-site. Appropriate dis-470 cussion and notification to the ambulance/paramedic service 471 should occur if reperfusion strategies change within a net-472 work/district. This may have the advantage of minimising 473 infection risk to staff in network referral centres and also 474 somewhat mitigate risk of declining staffing levels as they 475 may be a back-up team. The latter would require cross-476 credentialling of cardiologist privileges across health net-477 works/districts. Notably this is already the ''pharmaco-478 invasive\" reperfusion strategy practiced in regional Austra-479 lian and New Zealand centres. 480 Staff 481 Workforce Preparedness (See Catheter laboratory team Pre-482 paredness checklist Appendix 2) -All laboratory staff 483 should be trained in the appropriate donning and doffing 484 of PPE (see Spanish Society of Cardiology COVID-19 guide-485 lines [12] for Donning and Doffing PPE flow chart diagrams). 486 All staff should also be made aware of the lab locations where 487 PPE is kept for security and efficiency reasons. Online PPE 488 education is usually available through the hospital system 489 [For example, NSW health is proactively communicating the 490 Clinical Excellence commission (CEC)'s PPE guidelines 491 which are available on its website [13]]. 492 PPE Inventory management -The Catheter Laboratory 493 Nursing unit Manager and Director should both be active in 494 managing the supply of PPE to staff as this is essential 495 equipment to allow procedures to be undertaken. Systems 496 such as H-trak can aid this process and an active inventory 497 management approach is encouraged. It is likely when PPE is 498 not available then procedures may be cancelled or alternative 499 therapies (such as fibrinolysis for STEMI) instituted.",
            "latex": null,
            "type": "figure"
        },
        "FIGREF6": {
            "text": "be performed as this will identify issues early 503 and serve to increase ''team preparedness\". ''Practice runs\" 504 with full PPE for the team can be performed on low-risk 505 patients but this will expend PPE supply. Clinical nurse 506 educators and consultants should take a major role in this 507 preparation since this can alleviate staff stress and anxiety.",
            "latex": null,
            "type": "figure"
        },
        "FIGREF7": {
            "text": "However ''procedural stress\" will always occur during a 509 case.510Staffing Levels -Primary PCI is a resource intensive this article in press as:Lo  STH, et al. Consensus Guidelines for Interventional Cardiology Services Delivery During COVID-19 Pandemic in Australia and New Zealand. Heart, Lung and Circulation (2020), https://doi.org/10.a service. Health status of ''isolated\" teams should 522 be monitored on a daily basis and regular reported to 523 central cardiology management unit as to its availabil-524 ity/health deployability. Fragmentation into separate 525 teams mitigates the risk of interruption to essential service 526 delivery due to the enforced absence of medical and/or 527 nursing staff with specialised skills as the result of either 528 exposure to or infection with COVID-19. They can work on 529 a rotating basis in shifts. Discontinuity of ward patient care 530 is a disadvantage but the strategy serves to better ensure 531 medical staff availability. However, it may not be possible 532 in very small cardiology departments. Agreement from 533 hospital Human Resources and executive administration 534 would be required. 535 It has also been suggested that sequestering ''at risk\" staff 536 (> 65 years with co-morbidities) from frontline care of 537 COVID-19 patients would be reasonable as they would have 538 a 3-fold mortality [14] if infected. This would depend on the 539 age of the workforce and the impact on staffing levels to 540 deliver services. Other ''at risk\" staff include immunocom-541 promised and those with chronic health conditions regardessential staff necessary for the performance of the 546 procedure should be within the laboratory with all the doors 547 closed. There should be an adequate microphone system for 548 communication between the proceduralist and the cardiac 549 technologist/Radiographer/nurse supporting the case in 550 the control room. It may be good practice to have a ''clean\" 551 scout nurse outside the laboratory to obtain consumables 552 and pass into the laboratory. In 'closed' laboratories geo-553 graphically within an operating theatre environment, ''foot 554 traffic\" is generally minimised. ''Open laboratories\" are 555 prone to unnecessary people passing through which 556 increases infection risk. Notifications should be made to 557 reduce unnecessary ''foot traffic\" within the cardiac cathe-558 terisation laboratory for non-essential staff members. How-559 ever, despite reducing in-lab staffing levels, it may be 560 necessary to have an additional nurse outside the lab to 561 act as a ''clean scout\". 562 Staff Mental Health The lack of PPE resulting in COVID-19 infection (and 563 subsequent mortality risk) as well as wearing PPE results 564 in increased anxiety in catheter laboratory staff members 565 [15]. Experience from China during COVID-18]. Deliberate absenteeism may result from height-573 ened stress in a pandemic leading to healthcare worker 574 social isolation and low staffing levels. Clear and updated 575 information regarding pandemics may aid in reducing 576 concern [19]. Institutions should have strategies to mitigate 577 stress and anxiety in frontline staff during pandemics [19]. 578 Staff should be made aware of what services are available nursing staff are dedicated and usually prefer 582 working despite minor illness. This can be highly problem-583 atic during the COVID-19 pandemic, as minor symptoms 584 should not be ignored and early reporting will help identify 585 infected individuals with COVID-19 testing. Enhanced vigi-586 lance of all members of working staff aids early identification 587 of possible infection. 588 Frontline Physicians in Difficult Times The COVID-19 Pandemic has the potential to overwhelm 589 an entire country's health care infrastructure to manage 590 critically ill patients and exceeding Intensive care unit 591 capacities. Frontline medical staff providing essential 592 emergency services at personal risk are working under 593 extreme stress. There is no doubt that excellent catheter 618 C",
            "latex": null,
            "type": "figure"
        },
        "FIGREF8": {
            "text": "are at risk of creating aerosolised pathogens 642 (ie requiring oral/nasal suctioning (nausea/vomiting), use of 643 nebulisers, use of NIV/CPAP/BiPAP/high flow oxygen 644 should be intubated (by a PPE trained dedicated anaesthetic 645 team) prior to catheter laboratory transfer 646 Early intubation, sedation and possible paralysis should be 647 considered for patients who are thought to require high flow 648 oxygen supplementation approaching intubation or those 649 who have difficulty lying still.",
            "latex": null,
            "type": "figure"
        },
        "FIGREF9": {
            "text": "transfer, Cardiology registrar/trainee in charge of 653 transfer and proceduralist will be responsible for determin-654 ing the urgency and COVID-19 risk of the patient. Transfer 655 protocols (especially between Cardiology ward/CCU-Emer-656 gency department-ICU and the catheter lab) should be pre-657 pared so that risk is mitigated and patient flow is improved. 658 Patients with no or ''low exposure risk\" of COVID-19 can 659 be managed as per usual care 660 Patients with ''High exposure risk\" of COVID-19 will need 661 extra considerations and these steps should be adhered to 662 despite urgency of case and time delay: 663 -Dedicated laboratory will be locked and sealed for cleaning 664 for a prolonged period after the procedure. 665 -Cleaning staff should also be informed and trained regard-666 ing their protection 667 -Staff to ensure that complete set of level C PPE are available 668 for primary operator, scrub nurse (may be omitted), scout 669 nurse and registrar/fellow (may be omitted). Additional 670 PPE to be ready in case additional personnel are needed in 671 the room (5 sets total). Hand sanitisers to be made ready 672 just outside the procedure room for PPE removal. Two 673 additional hazard bins for PPE (one just inside and one 674 just outside procedure room doors) to be made ready 675 -All staff listed above together with radiographer and tech-676 nician will have to ready and available in catheter lab start-677 up has been performed and deemed functional. 678 -Staff to be in the catheter lab procedure area (operator, 679 registrar/fellow, scrub nurse and scout nurse to don PPE, 680 lead gown). Operator and scrub nurse to scrub and gown. 681 Scout nurse and registrar/fellow to remain unscrubbed in 682 PPE. 683 -Technician and radiographer to remain in control room Need to ensure there will be adequate personnel for physi-695 cal transfer of patient onto catheter lab bed (Patient is not to have any delayed waiting in corridors and 701 will need direct transfer into the catheter lab procedure 702 room from their origin (should have transfer protocols 703 organised). 704 -Ideally, all personnel in PPE who transferred the patient 705 should stay in the catheter lab throughout procedure. Other-706 wise, they will have to remove PPE in lab prior to exit from lab 707 through main doors and not control room with hand sanitisers 708 used outside the procedure room, and re-don PPE prior to 709 returning to collect patient at the end of the procedure.",
            "latex": null,
            "type": "figure"
        },
        "FIGREF10": {
            "text": "All non-essential equipment (balloons, wires, catheter, 711 stents) should be stored outside the procedure room, pref-712 erably in cabinets. 713 -Additional equipment required from outside the proce-714 dure area should be obtained by technician or radiographer 715 and be passed via slightly opened control room door with 716 no contact between personnel 717 -If a MET call is activated, staff in control room to ensure 718 only essential MET call staff enter room and that all MET 719 call staff don PPE prior to entering the procedure room via 720 main door (not via the control room). 721 -Automatic chest compression devices such as LUCAS II are 722 preferred of CPR is contemplated. 723 -Upon completion of the procedure, any additional person-724 nel who needs to come into the procedure room to help 725 with patient transfer/transport will need to don full PPE 726 -All scrubbed staff to stay in room until patient transferred 727 out of room directly to destination. 728 -Staff to then remove surgical scrub and PPE as per protocol 729 one person at a time (take time to do this properly) inside 730 procedure room until last step (mask and goggles, and last) 731 to be removed outside room. 732 -Footwear: Encourage the use of washable footwear such as 733 clogs that can be cleaned 734 -Staff to ensure that they adhere to every step of PPE 735 removal including hand scrub/wash at the end. 736 -Procedure area and lab to undergo terminal clean (often 737 cleaning commences 30 min after procedure) and the time 738 for lab re-use as per infection control recommendations in 739 various centres. Procedure area of lab to be sealed until 740 after terminal clean. If equipment needed urgently from the 741 room, PPE will have to be donned to enter.",
            "latex": null,
            "type": "figure"
        },
        "FIGREF12": {
            "text": "Driggin E, Madhavan MV, Bikdeli B, Chuich T, Laracy J, Bondi-Zoccai G, 911 et al. Cardiovascular considerations for patients, health care workers,",
            "latex": null,
            "type": "figure"
        },
        "TABREF0": {
            "text": "Fibrinolysis may be considered (or even preferred) in STEMI reperfusion in hospitals even with catheter Postponement of non-urgent procedures to reduce demand on beds, use of PPE, staff and other resources Postpone non-urgent TAVI and Mitra-clip TM and all ASD/PFO and LAA closure procedures 74 5 In health care networks, centralisation of primary angioplasty services may be possible 76 6 Training of staff in proper PPE donning and doffing is Fragmentation of staff into teams is desirable and can mitigate risk of exposure and impact on staffing levels to Working closely with ED, ICU and Anaesthetics from planning to processes promotes efficiency and reduces Background: COVID-19 pandemic is rapidly progressing worldwide and the impact on societies is constantly evolving. This consensus document highlights the clinical challenges and seeks to guide Australian and New Zealand cardiology units in their decisions to how best reconfigure interventional cardiac services during this difficult time. There is no ''one-size fits all\" recommendation and each unit may be faced with unique challenges. It is possible if the worst-case scenario occurs that little or no service provision is possible. Main challenge: COVID-19 appears to be more virulent than other common respiratory tract viral infections such as H1N1/ influenza. Bringing a confirmed or suspected COVID-19 patient to the cardiac catheterisation laboratory will expose all laboratory staff to the risk of infection and 100 disable laboratory use for a prolonged period of time for 101 terminal cleaning.Ideally all patients undergoing urgent cardiac catheterisation in the absence of a negative COVID-19 test should be 104 treated as potentially infected as in Italy[1]. Internationally a shortage of personal protective equipment (PPE) has contributed to frontline health care workers (HCW) infections and",
            "latex": null,
            "type": "table"
        },
        "TABREF1": {
            "text": "Johns Hopkins Coronavirus Resource Center Map [3] 126 127 NSW VIC QLD SA WA NT TAS AUS NZ 128",
            "latex": null,
            "type": "table"
        },
        "TABREF4": {
            "text": "Balmer C, Pollina E. Italy's Lomb Q14 ardy asks retired health workers to join 905 coronavirus fight. World Economic Forum, Reuters; 2020, https://www. weforum.org/agenda/2020/03/italys-lombardy-etired-health-workers 907 -coronavirus-covid19-pandemic. [3] Johns Hopkins University. Coronavirus Resource Centre International Map. https://coronavirus.jhu.edu/map.html.",
            "latex": null,
            "type": "table"
        }
    },
    "back_matter": []
}